REZOLUTE, INC. Deferred Offering Costs
REZOLUTE, INC. (RZLT) had Deferred Offering Costs of $32.00 thousand as of 2020-12-31, per its 10-Q filed 2021-02-10.
Discontinued › Balance Sheet › Assets › Assets, Current
us-gaap:DeferredOfferingCosts · last filed 2021-02-10
- 2020-12-31: Deferred Offering Costs $32.00K.
- 2020-09-30: Deferred Offering Costs $129.00K.
- 2019-12-31: Deferred Offering Costs $0.00.
- 2019-09-30: Deferred Offering Costs $21.00K.
| Period end | Deferred Offering Costs |
|---|---|
| 2020-12-31 | $32.00K 10-Q · filed 2021-02-10 |
| 2020-09-30 | $129.00K 10-Q · filed 2020-11-12 |
| 2019-12-31 | $0.00 10-Q · filed 2021-02-10 |
| 2019-09-30 | $21.00K 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |